Mangoceuticals Inc (MGRX)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-09
$0.42+1.22%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-09
Broken: Primary pillar broken — TRT segment revenue growth: metric not reported.
Mangoceuticals focuses on TRT as its main growth driver. Management aims to reverse revenue decline from $109K in 2025-Q1 to $67K in 2026-Q1. Recent M&A deals and private placements provide capital for growth. The company trades at a low valuation with optionality for recovery.
The company is loss-making with negative free cash flow yield of -0.8%. Revenue is declining and management progress on growth is weak at 40%. Recent capital raises and delisting notices signal financial stress. The stock has fallen 32% from its high.
The market prices in a 37% implied 3-year growth but the company currently lacks revenue growth and profitability. Our fair value is $0.25, reflecting optionality but not a clear recovery. The stock is down 15% recently, reflecting selling pressure.
Breaks if: additional dilutive capital raises announced within next 4 quarters
Breaks if: free cash flow yield remains negative through FY26
TRT revenue growth falls below 0% YoY next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. MGRX is currently navigating through a volatile management phase while attempting to commercialize new technology and improve its financial performance.
The market appears to be pricing in a high valuation premium compared to peers, reflecting some optimism despite the company's loss-making status. There is a fragility in the valuation due to the expensive nature of the stock amid ongoing operational challenges.
Management has made progress in improving operating income, with notable reductions in losses. However, the company remains in a high-risk environment, and recent changes in leadership and M&A activity could impact future performance.
The future trajectory depends on management's ability to advance the commercialization of the Nuclea microreactor and regain compliance with Nasdaq listing requirements. Additionally, broader sector performance and economic indicators will play a crucial role in shaping MGRX's outlook.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company announced a business combination with Nuclea Energy. This deal supports the commercialization of Nuclea's microreactor technology. There are no new threats to the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, MGRX's performance will likely be influenced by its operational improvements and external market conditions. Not investment advice.